• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Neurostimulation device GammaSense by Cognito Therapeutics secures FDA Breakthrough Device Designation to explore Alzheimer’s Disease applications

January 14, 2021 by SharpBrains

Cred­it: The Picow­er Insti­tute @ MIT

Cog­ni­to Ther­a­peu­tics nets FDA break­through label for light, sound ther­a­py for Alzheimer’s dis­ease (Fierce Biotech):

Using spe­cif­ic fre­quen­cies of flash­ing lights and sounds to stim­u­late the brain’s elec­tri­cal activ­i­ty, Cog­ni­to Ther­a­peu­tics believes it can help treat Alzheimer’s dis­ease by ener­giz­ing neu­rons and reac­ti­vat­ing the immune system.

Described as sim­i­lar to a strobe light, but much faster, Cognito’s Gam­maSense stim­u­la­tion sys­tem is built into a pair of opaque glass­es worn with a set of head­phones. The dai­ly treat­ment has shown pos­i­tive effects in mice, with changes in the brain’s hip­pocam­pus and audi­to­ry cor­tex includ­ing the reduc­tion of amy­loid plaques, accord­ing to a study pub­lished in Cell.

Now, with the treat­ment approach being stud­ied in place­bo-con­trolled human tri­als, the FDA said it has seen enough ear­ly clin­i­cal data to label the device as a poten­tial break­through therapy—affording the com­pa­ny pri­or­i­ty review and addi­tion­al oppor­tu­ni­ties to work with agency offi­cials through the project’s clin­i­cal and com­mer­cial development.

The Announcement:

Cog­ni­to Ther­a­peu­tics Receives FDA Break­through Device Des­ig­na­tion for Next-Gen­er­a­tion Dig­i­tal Ther­a­peu­tic in Alzheimer’s Dis­ease (press release):

Cog­ni­to Ther­a­peu­tics, a clin­i­cal-stage com­pa­ny lead­ing the devel­op­ment of a new class of dis­ease-mod­i­fy­ing dig­i­tal ther­a­peu­tics to treat neu­rode­gen­er­a­tive dis­or­ders, announced today its lead prod­uct has received Break­through Device Des­ig­na­tion from the U.S. Food and Drug Admin­is­tra­tion (FDA) for the treat­ment of cog­ni­tive and func­tion­al symp­toms asso­ci­at­ed with Alzheimer’s dis­ease. The prod­uct, a non-inva­sive neu­rostim­u­la­tion device using gam­ma fre­quen­cy tech­nol­o­gy, is the first in the Company’s pipeline of dig­i­tal ther­a­peu­tics for neu­rode­gen­er­a­tive dis­eases and oth­er chron­ic indications…

“I am encour­aged by Cognito’s inno­v­a­tive approach,” said Allan Lev­ey, M.D., Ph.D., Pro­fes­sor and Chair­man of the Depart­ment of Neu­rol­o­gy at Emory Uni­ver­si­ty and Direc­tor of the Emory Goizue­ta Alzheimer’s Dis­ease Research Cen­ter. “This strat­e­gy trans­lat­ing recent advances in non-inva­sive mod­u­la­tion of brain activ­i­ty with sen­so­ry stim­u­la­tion with light and sound has the poten­tial to be an urgent­ly need­ed safe, non-inva­sive, and effec­tive treat­ment for mil­lions of indi­vid­u­als with Alzheimer’s disease.”

The Study:

Mul­ti-sen­so­ry Gam­ma Stim­u­la­tion Ame­lio­rates Alzheimer’s‑Associated Pathol­o­gy and Improves Cog­ni­tion (Cell):

  • Abstract: We pre­vi­ous­ly report­ed that induc­ing gam­ma oscil­la­tions with a non-inva­sive light flick­er (gam­ma entrain­ment using sen­so­ry stim­u­lus or GENUS) impact­ed pathol­o­gy in the visu­al cor­tex of Alzheimer’s dis­ease mouse mod­els. Here, we designed audi­to­ry tone stim­u­la­tion that drove gam­ma fre­quen­cy neur­al activ­i­ty in audi­to­ry cor­tex (AC) and hip­pocam­pal CA1. Sev­en days of audi­to­ry GENUS improved spa­tial and recog­ni­tion mem­o­ry and reduced amy­loid in AC and hip­pocam­pus of 5XFAD mice. Changes in acti­va­tion respons­es were evi­dent in microglia, astro­cytes, and vas­cu­la­ture. Audi­to­ry GENUS also reduced phos­pho­ry­lat­ed tau in the P301S tauopa­thy mod­el. Fur­ther­more, com­bined audi­to­ry and visu­al GENUS, but not either alone, pro­duced microglial-clus­ter­ing respons­es, and decreased amy­loid in medi­al pre­frontal cor­tex. Whole brain analy­sis using SHIELD revealed wide­spread reduc­tion of amy­loid plaques through­out neo­cor­tex after mul­ti-sen­so­ry GENUS. Thus, GENUS can be achieved through mul­ti­ple sen­so­ry modal­i­ties with wide-rang­ing effects across mul­ti­ple brain areas to improve cog­ni­tive function.

News in Context:

  • Neu­ro­mod­u­la­tion device Reliv­ion gets FDA clear­ance to help patients with major depres­sion who don’t ben­e­fit from anti­de­pres­sant medications
  • New report: Empow­er­ing 8 Bil­lion Minds via Eth­i­cal Devel­op­ment and Adop­tion of Neurotechnologies
  • We need to rethink neu­ro­science. And you can help us
  • Five rea­sons the future of brain enhance­ment is dig­i­tal, per­va­sive and (hope­ful­ly) bright

Update by Dr. Lew Lim, Founder & CEO of Vielight from Sharp­Brains

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: amyloid plaques, breakthrough device, breakthrough therapy, cognitive-symptoms, Cognito Therapeutics, digital therapeutics, FDA, GammaSense, hippocampus, neurodegenerative-diseases, neuromodulation, Neurons, neurostimulation, Neurotechnology, treat Alzheimer’s disease

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,619 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy